Skip to content

Author

M. Hidalgo

We have 2 of 26 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More.

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy and has long been regarded as a therapeutic "drug graveyard", with modest gains from cytotoxic combination chemotherapy and numerous novel agents failing to show benefit in clinical trials. The quest to directly target RAS has moved from concept...

Peter Y. Yu, Paul E. Oberstein, A. Maitra et al. · 0 citations
#gene editing Review Sep 2026

Abstract A129: Phasic Hedgehog Inhibition Primes the Pancreatic Tumor Microenvironment to Enhance Chemoimmunotherapy in Metastatic Pancreatic Ductal Adenocarcinoma: Results from the Phase 1b/2 NUMANTIA Trial

CAF-directed stromal priming as a strategy to enhance chemoimmunotherapy and warrant evaluation in randomized studies with integrated biomarker analyses are supported.

V. S. Kalluri, B. Bockorny, Evelio Perea Borobio et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.